Exciting developments! Roche’s new experimental drug for SMA is moving to late-phase clinical trial in SMA types 2 and 3.
Come and join our meetup on Monday 18 September to talk about access to SMA treatments and what we all need to do to receive it.
On 23 August 2017, TreatSMA along with SMA Trust, SMA Support UK and MD UK signed a letter addressed to the Head of Specialised Commissioning Team at NHS England. We urged a review of the published commissioning policy for inclusion of SMA 1 patients in the Expanded Access Programme of nusinersen.
Roche shared an update on the safety of RG7916.
NHS England has published an Interim Commissioning Policy on nusinersen EAP.
Dear Community, During the last few weeks NHSE and Biogen has been discussing the support for EAP. As we know, NHSE current official position is that they are not willing to fund additional auxiliary costs associated with Spinraza administration. Whilst…
Today a group of TreatSMA families attended a meeting of the All-Party Parliamentary Group for Muscular Dystrophy at the House of Lords.
First ever treatment for life-devastating condition is approved by European Commission!